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LYs and $271.3 billion (B) due to cervical cancer alone over the 
next 20 years. Based on a realistic linear investment model, RT 
yields an additional 9.8M LYs (2.9M in LIC, 4.7M in LMIC, and 2.2M 
in UMIC) over 20 years, a $53.2B net increase in economic 
productivity ($2.6B in LIC, $16.4B in LMIC, and $34.2B in UMIC), 
and a broader societal net gain of $137.5B ($10.3B in LIC, $44.8B 
in LMIC, and $82.4B in UMIC). The additional investment 
necessary for HDR brachytherapy, an essential component of 
curative treatment, was only 5.5% greater than EBRT alone. 
Conclusions: The failure to ensure global availability of EBRT and 
BT to treat cervical cancer would result in enormous human and 
economic consequences over the next two decades. This loss 
would occur before the benefits of primary cancer prevention 
strategies, such as HPV vaccination, are realized. The present 
study demonstrates that a realistic investment strategy over the 
next 20 years may yield a net economic benefit of up to $150B 
USD, and potentially further benefits beyond that point in time. 
These findings support the value of scaling-up of EBRT and BT to 
treat cervical cancer and help to justify their inclusion in 
national cancer control planning. 
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Purpose: To compare emergency department (ED) use between 
patients with cancer and a matched cancer-free cohort of 
individuals and to examine the association between ED use and 
time to death. 
Methods and Materials: Data were from the Manitoba Centre for 
Health Policy Data Repository and included cancer registry, 
hospital discharge abstracts, physician billing claims, ED visits, 
and vital statistics. The cancer cohort included adults (age 18+) 
with selected cancer diagnoses (breast, colorectal, lung and 
prostate) made between 2007 and 2011. Rates of ED utilization 
were compared during three time periods (pre-, peri-, and post-
diagnosis) using generalized estimating equations between 
cancer patients and cancer-free individuals matched 1:1 on age, 
sex, and Charlson comorbidity score. The association between 
ED use and time to death was tested using a multivariable Cox 
proportional hazards regression model. 
Results: A total of 5569 patients with breast (n = 1555), 
colorectal (n = 1327), lung (n = 1437), and prostate (n = 1250) 
cancer were included. When comparing ED utilization between 
cancer cases by site and their matches only lung cancer showed 
a significant increase during the pre-diagnosis period (relative 
rate [RR] 1.38 [95% confidence interval 1.18-1.62], p < 0.0001). 
ED utilization was increased during the peri-diagnosis period for 
breast (RR 1.74 [1.31-2.32], p = 0.0001), colorectal (RR 2.44 
[1.72-3.45], p < 0.0001), lung (RR 4.51 [3.61-5.63], p < 0.0001), 
and prostate (RR 3.10 [2.14-4.47], p < 0.0001) cancer. In the 
post-diagnosis period, ED utilization was increased for breast (RR 
1.45 [1.26-1.67], p < 0.0001), colorectal (RR 1.40 [1.11-1.76, p = 
0.0005), and lung (RR 2.28 [1.94-2.67], p < 0.0001) cancer. ED 
use in the year prior to diagnosis was associated with time to 
death for prostate cancer (hazard ratio [HR] 1.12 [95% CI 1.02-
1.24], p < 0.02) while ED use in the post-diagnosis period was 
associated with time to death for breast (HR 1.27 [1.18-1.37], p 
< 0.0001), colorectal (HR 1.11 [1.04-1.18], p = 0.0012), and lung 
(HR 1.10 [1.06-1.14], p < 0.0001) cancer. 
Conclusions: The pattern of ED utilization varies with cancer site 
and time from diagnosis. All cancer sites were associated with 
increased ED use around the time of diagnosis, while patients 
with breast, colorectal, and lung cancers also showed increased 
ED use in the post-diagnosis period. Additional cancer-related 
urgent care services during the peri- and post-diagnosis periods 
may alleviate the frequency of ED visits among patients with 
cancer. 
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Purpose: Patients with FIGO Stage II endometrial cancer (EC) are 
generally treated surgically, with risk-adapted adjuvant 
radiotherapy (external beam radiotherapy (EBRT) and/or vaginal 
vault brachytherapy (BT) boost) still suboptimally defined. With 
changing surgical practices in nodal assessment and/or 
resection, opportunity exists for selected patients to receive less 
intensive adjuvant therapy, with the goal of lessening treatment-
related morbidity. In this single-institutional review, we explore 
outcomes of Stage II EC patients treated with adjuvant 
“minipelvis” (MP)-EBRT (a field covering at least the surgical 
bed, vaginal vault, and parametria, but not the classical elective 
nodal regions) +/- BT. 
Methods: Women with pathologic Stage II EC receiving post-
operative MP-EBRT from 2000 onwards were reviewed. 
Demographics, disease characteristics, treatment details, 
survival, and recurrence data were collected. Three-year 
relapse-free survival (RFS) and overall survival (OS) were 
calculated from the date of surgery (Kaplan-Meier method). 
Median RFS and OS were compared between those receiving MP-
EBRT+BT and those receiving MP-EBRT alone (log rank test). 
Univariate analysis was performed (binary logistic regression) to 
determine factors associated with relapse. 
Results: n = 42 patients (median age 63 years [36-86]) received 
adjuvant MP-EBRT (2000-2015), with median follow up 27 months 
(2-105). n = 37 (88%) had pelvic lymph node dissection. 
Endometrioid adenocarcinoma was predominant (71%) over other 
histologies. n = 20 had Grade 3 disease, n = 18 had deep (> 50%) 
myometrial invasion (MI), and n = 22 had lymphovascular invasion 
(LVI). n = 10 received adjuvant chemotherapy. MP-EBRT fields 
had conventional inferior and lateral borders and height less than 
12 cm (range 7.8-11.8). Dose fractionation was typically 45 Gy in 
25 fractions (40-52.6 Gy/20-25), and 32 (76%) received 
subsequent HDR BT boost, typically 15 Gy in three fractions (15-
18 Gy/3) prescribed to vaginal surface. Ten patients relapsed 
(one vaginal recurrence, three in pelvis outside the field, six 
distant), four (40%) of those not receiving BT versus 19% of the 
BT group (OR 3.5, 95%CI 0.7-16.9, p = 0.125). Median time to 
relapse was 20 months (10-32). Tumour grade, LVI, and MI were 
not significantly associated with relapse. Three-year RFS and OS 
were 74% and 92% respectively. 
Conclusions: In this small series, early outcomes following 
adjuvant MP-EBRT for Stage II EC align with those reported for 
conventional adjuvant EBRT, suggesting that this is a reasonable 
approach. Only three patients relapsed in the pelvis outside of 
the field. Further characterization of tumour and toxicity 
outcomes can help to better define the population most likely to 
benefit from MP-EBRT, and the value of BT boost in this setting. 
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Purpose: To document the practice of brachytherapy (BT) and 
external beam radiotherapy (EBRT) for management of cervical 
cancer across Ontario, Canada with a population of 13.6 million. 
Methods and Materials: An electronic survey (SurveyMonkey) 
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was sent to all 14 provincial cancer centres in 2013. The survey 
included 72 questions in four different categories: 
general/demographic, pre-treatment assessment, EBRT and BT 
questions.  
Results: The response rate was 100%. Ten out of 14 centres 
treated cervical cancer patients and had a dedicated 
brachytherapy suite. All 10 centres that treated cervix cancer 
had a peer review process for quality assurance (QA). Nine 
centres had written treatment planning and delivery protocol 
and five centres used a specific plan evaluation protocol for 
organs at risk for EBRT. The standard EBRT technique was 4-field 
box in eight centres and one centre used IMRT if treating the 
para-aortic nodes simultaneously; one centre did not respond. 
The dose/fractionation scheme to the whole pelvis was 45-50 Gy 
in 1.8-2 Gy per fraction in all but one centre. Nine centres used 
image verification at some point during EBRT. All ten centres 
used HDR brachytherapy and one centre also used PDR 
brachytherapy to treat cervix cancer patients.  
Brachytherapy was performed under general anesthesia, regional 
anesthesia and conscious sedation in four, one and five centres, 
respectively. Only one centre offered interstitial brachytherapy. 
The majority of centres (eight of 10) used ultrasound image 
guidance for intrauterine applicator insertion. For treatment 
planning two centres used CT and MRI, four centres used CT only 
and four centres used orthogonal x-rays. GEC-ESTRO guidelines 
were used in three centres for target volume delineation and in 
five centres for organs at risk (OAR) dose constraints. Nine 
centres prescribed and reported dose to Point A. Volumetric dose 
prescription was performed in one centre and four centres 
reported dose to a target volume. Eight centres reported dose to 
OARs. The number of BT applicator insertions varied significantly 
between the centres ranging from one to six. The dose 
prescription was also variable ranging from 5.5 Gy to 8 Gy per 
fraction. 
Conclusions: The main findings from the survey were the 
variation in the BT dose fractionation and treatment planning 
used in the regional cancer centres while there was a general 
uniformity in peer reviewed QA, written institutional treatment 
protocol, EBRT technique, dose fractionation scheme and use of 
HDR BT across the province. This study shed light on the need to 
implement a harmonized evidence-based brachytherapy practice 
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Purpose: The British Columbia Cancer Agency radiotherapy (RT) 
program started the Prospective Outcomes and Support Initiative 
(POSI) at all six centres in 2013 to collect and utilize patient 
reported outcomes (PROs) for patients receiving palliative intent 
RT. In 2015 it expanded to patients receiving curative intent RT, 
starting with the gynecological (gyne) tumour group. We sought 
to describe the success in expanding to non-palliative sites. 
Methods and Materials: Five validated questionnaires, the EPIC 
Bowel 2 (2002), EPIC Urinary 2 (2002), PRO-CTAE GI toxicity, 
EORTC QLQ CX24, and the EQ5DL were selected as the PROs of 
interest by the gyne tumour group. The questionnaires were 
converted to tablet format, and data was entered directly by 
patients via tablet at time of RT, and each subsequent follow up 
(FU). Some centres choose to also administer the questions 
weekly during RT, which is categorized as FU below in comparing 
scores to baseline. The results of the questionnaires were made 
available immediately to Radiation Oncologists, viewable in the 
RT electronic medical record, and in a local intranet POSI Portal. 
Descriptive Statistics were used to present accrual data and 
results of the PRO questionnaires. 
Results: From March 2015 to January 2016, 480 gyne patients 
were approached by POSI on 1007 occasions (i.e. baseline, on 
treatment, or FU), with a 97% response rate. However, not all six 
British Columbia Cancer Agency centres participated at that 
time, with Vancouver and Victoria starting in March, Abbotsford 
in July, Kelowna in August, while Surrey and Prince George have 
not yet participated. The mean (and standard deviation) scores 
of the EPIC Bowel, EPIC Urinary, PRO-CTAE GI, EORTC QLQ CX24, 
and EQ5DL were 8.9 (9.4), 6.1 (7.3), 2.9 (3.4), 2.8 (3.5), and 8.8 
(3.2), respectively, with significantly (p < 0.05) worse scores at 
FU compared to baseline for each questionnaire, except the 
EQ5DL (p = 0.62). Of the 24 patients not accrued, 29% were unfit, 
21% had not interpreter available, and 50% declined. Among 
those who declined, 33% did at baseline, 17% at first repeat 
measure, 25% at second, and 25% at the third or later repeat 
measure. Among the 189 patients who reported PRO on more 
than one time interval, 72, 37, and 80 patients repeated the PRO 
2,3, and > 3 occasions respectively to date. 
Conclusions: Expansion of POSI to collect PRO in a radical 
tumour group appears feasible, though there have been barriers 
to expansion to all six British Columbia Cancer Agency centres, 
which will be explored. Despite the use of five validated 
questionnaires totaling 49 questions, the accrual rate is 
exceptional, and appears feasible weekly during radiotherapy. 
Expansion to other radical tumour sites will be used to test if 
these results are reproducible. Future plans are to test the 
impact of providing PRO data to clinicians, and to make gyne PRO 
data available for research and quality improvement initiatives. 
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Purpose: The EORTC 22881 boost trial showed a substantial 
benefit of delivering a radiotherapy boost to the tumour bed 
(RTB) in women aged 40 years and younger, with an improvement 
in 10-year local relapse-free survival (LRFS) of 10%. However, 
this trial was carried out in an era where pre-menopausal women 
did not receive adjuvant hormone therapy (HT). We sought to 
determine how the use of HT and RTB changed in a population-
based cancer care program in response to new practice 
guidelines, and whether this had an impact on LRFS. We also set 
out to determine whether the anticipated benefit of a RTB for 
young women was observed in the era of routine HT.  
Methods and Materials: A provincial database was used to 
identify all women 40 years and younger with breast cancer that 
met the inclusion criteria of the EORTC 22881 trial: treated with 
whole breast radiotherapy after breast conserving surgery, 
margin negative (not at ink), and Stage I and II. The percentages 
of women receiving HT and RTB were compared across three Eras 
that were defined, a priori, with a three-month delay allowing 
for implementation of the practice changes: Era 1 (pre-HT, pre-
boost) January 1996-September 1998; Era 2 (HT, pre-boost) 
January 1999 - September 2001; Era 3 (HT and boost) January 
2002 - September 2004. LRFS was calculated using the Kaplan-
Meier method and the three eras compared using a log rank test. 
Factors significant at < 0.3 on univariate analysis were included 
with Era in a multivariable (MVA) Cox model. 
Results: The study included 411 patients: 130 in Era 1, 142 in Era 
2, and 139 in Era 3. The use of adjuvant HT increased over time, 
with 8% use in Era 1, 45% in Era 2 and 54% in Era 3 (p = < 0.001) 
For estrogen receptor (ER) positive cancers, HT use was higher: 
13% in Era 1, 68% in Era 2 and 82% in Era 3 (p = < 0.0001). The 
